同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02410 同源康医药-B

休市中 09-04 16:08:03

6.205

+0.140

+2.31%

最高6.385	最低6.065	成交量771.79万
今开6.065	昨收6.065	日振幅5.28%
总市值23.58亿	流通市值23.30亿	总股本3.80亿
成交额4,819万	换手率2.06%	流通股本3.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":6.205,"timestamp":1788509283006,"preClose":6.065,"halted":0,"volume":7717892,"delay":0,"changeRate":0.023083264633140917,"floatShares":375457818,"shares":380065818,"eps":-0.9350049002312911,"marketStatus":"休市中","change":0.14,"latestTime":"09-04 16:08:03","open":6.065,"high":6.385,"low":6.065,"amount":48191759,"amplitude":0.052762,"askPrice":6.21,"askSize":48000,"bidPrice":6.205,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":-0.6562740956917168,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":6.065,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.7791049959241938,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02410","defaultTab":"news","newsList":[{"id":"1187462223","title":"同源康医药-B 8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1187462223","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187462223?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:49","pubTimestamp":1788425388,"startTime":"0","endTime":"0","summary":"2026年9月3日，浙江同源康医药股份有限公司（股票代码：02410，股票简称“同源康医药-B”）发布2026年8月股份变动月报表。公告显示，截至2026年8月31日，公司注册股本总额为人民币380,065,818元，普通股H股共计380,065,818股，面值均为人民币1元，较上月底无任何增减变动。\n公告同时明确，当月未发生新发行、购回、注销或库藏股变动，也无股份期权或其他股权激励计划调整。截至8月底，公司已发行股份数为380,065,818股，公众持股量符合香港联合交易所相关规定，整体股本结构保持稳定。本次公告由执行董事、董事长兼总裁吴豫生签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824858","title":"港股异动 | 同源康医药-B(02410)午后涨超9% EGFR-TKI氘申艾替尼获批一线治疗晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664824858?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:30","pubTimestamp":1788417020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超9%。消息面上，同源康医药近日宣布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已正式获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。同源康预计收取7亿元人民币现金首付款及股份认购款，以及最高20.6亿元人民币的注册里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","02410","BK1161","BK1574","BK4585","VXUS","BK4588","159938","BK1515","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662583930","title":"同源康(02410)1类新药氘申艾替尼片获批附条件上市，为EGFR突变肺癌脑转移临床治疗带来新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2662583930","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662583930?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:27","pubTimestamp":1787884074,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年8月27日，港股创新药企同源康医药宣布，公司自主研发的1类新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局批准附条件上市，用于具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037097","title":"同源康医药-B早盘高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037097","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037097?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:35","pubTimestamp":1787880900,"startTime":"0","endTime":"0","summary":"模拟交易客户端同源康医药-B早盘高开近15%，截至发稿，股价上涨14.99%，现报7.825港元，成交额275.83万港元。8月27日晚，同源康医药公布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-28/doc-inipvrtx8899235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK1515","09939","BK1161","159992","IBBQ","IPOS","LNGR","02410","06978","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037468","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 创新药TY-9591片获批准附条件上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037468?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:24","pubTimestamp":1787880257,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","09939","BK1515","02410","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151775479","title":"同源康医药-B（02410）自主研发EGFR-TKI甲磺酸氘申艾替尼片获NMPA附条件上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1151775479","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151775479?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:24","pubTimestamp":1787837048,"startTime":"0","endTime":"0","summary":"2026年8月27日，同源康医药-B发布自愿公告称，其自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得中国国家药品监督管理局附条件上市批准。该药适用于携带表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。同源康医药-B提醒，尚无法保证甲磺酸氘申艾替尼片最终能够成功商业化，投资者买卖公司股份时需审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117102070","title":"同源康医药-B（02410）将63,222,744股H股发行最后截止日期延至2026年9月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=1117102070","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117102070?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:21","pubTimestamp":1787224881,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司8月20日发布公告称，公司与齐鲁方面就许可及合作事项下拟向认购方发行63,222,744股H股的认购协议，最后截止日期由2026年8月20日顺延至2026年9月20日。根据2026年7月21日公告，该认购事项须在认购协议项下的先决条件达成或获得豁免后方可完成；若相关条件未能在最后截止日期前落实，认购协议将被终止。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660598654","title":"港股异动 | 同源康医药-B(02410.HK)早盘涨超6% 上半年亏损显著收窄 TY-9591商业化加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2660598654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660598654?lang=zh_cn&edition=full","pubTime":"2026-08-18 11:05","pubTimestamp":1787022306,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1515","09939","BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660806764","title":"同源康医药-B(02410)上半年亏损大幅收窄 产业化及商业化布局持续取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2660806764","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660806764?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:39","pubTimestamp":1786970394,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 公布2026年中期业绩，研发成本为9494.3万元，同比增长7%;行政开支6255.4万元，同比增长61.3%;母公司拥有人应占亏损2489.7万元，同比收窄77.81%。此外，公司于2026年1月获浙江省药品监督管理局颁发的《药品生产许可证》。本次获得药品生产许可证，预期将对公司扩大产能及拓展市场产生长远的积极作用，为后续开展商业化生产奠定基础。此举为公司透过借助齐鲁的专业知识及网路达成其商业化里程碑的重要举措。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","02410","BK1515","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105087400","title":"同源康医药-B（02410）披露董事会及四大委员会最新组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1105087400","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105087400?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:16","pubTimestamp":1786968984,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司8月17日公告，公司董事会由九名董事组成，其中执行董事1名、非执行董事4名、独立非执行董事4名。本次公告日期为2026年8月17日，公司未对上述董事及委员会设置作出其他补充说明。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660504487","title":"同源康医药-B(02410.HK)：蒋鸣昱辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2660504487","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660504487?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:10","pubTimestamp":1786968601,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02410","BK1161","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182291744","title":"同源康医药-B（02410）发布董事会变动及建议重选董事公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1182291744","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182291744?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:06","pubTimestamp":1786968373,"startTime":"0","endTime":"0","summary":"8月17日，同源康医药-B公告称，公司董事会收到蔣鸣昱博士的辞呈，其因投放更多时间从事其他商业事务，已辞任非执行董事及根据香港联交所证券上市规则第3.05条规定的授权代表，辞任自2026年8月17日起生效。蔣博士确认无任何与董事会及公司之间的意见分歧，亦无任何需提请股东及联交所关注的事项。董事会对其任职期间的贡献表示感谢。此外，公司将适时向股东派发载有建议重选董事详细资料的通函。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU2039709279.SGD","LU1993786604.SGD","HK0000320223.HKD","IE00B031HY20.USD","LU1303224171.USD","KURE","BK1500","02359","09688","IE00BZ08YT58.USD","LU1813983027.USD","LU1951186391.HKD","01093","LU1226288170.HKD","BK1588","01548","LNGR","LU0315179316.USD","03692","BK1515","LU2125910500.SGD","LU0326950275.SGD","06978","BK1521","09969","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1583","IBBQ","LU1152091168.USD","159992","BK1576","IE00B543WZ88.USD","LU0072913022.USD","BK1617","06855","02410","MEDX","LU1226287792.SGD","06160","IE00B5MMRT66.SGD","LU1226287875.USD","LU2488822045.USD","HK0000306685.HKD","LU0880133367.SGD","02268","BK1161","02228","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104587482","title":"同源康医药-B（02410）将于8月17日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1104587482","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104587482?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:22","pubTimestamp":1785921722,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司（股票代码：02410，股票简称：同源康医药-B）8月5日公告称，公司董事会会议将于2026年8月17日（星期一）举行。届时，董事会将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并讨论是否派发中期股息（如有）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120386864","title":"同源康医药-B更新7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120386864","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120386864?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:11","pubTimestamp":1785921109,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司（同源康医药-B，股票代码：02410）于2026年8月5日发布截至2026年7月31日的股份变动月报表。报告显示，公司期末注册股本为人民币380,065,818元，各类已发行普通股合计380,065,818股，面值每股人民币1元，库藏股数量为0股。\n报告期内，公司无新增发行、购回、注销或库藏股变动，股本结构保持稳定。公司亦表示，其已满足香港联交所对于上市发行人最低公眾持股量不低于该类别股份总数的25%之规定。根据公告信息，本次月报由执行董事、董事长兼总裁吴豫生签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654972091","title":"同源康医药-B午后涨超5% 齐鲁制药获TY-9591独家商业化授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654972091","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654972091?lang=zh_cn&edition=full","pubTime":"2026-07-27 13:12","pubTimestamp":1785129120,"startTime":"0","endTime":"0","summary":"　　同源康医药-B盘中涨超6%，截至发稿，股价上涨5.39%，现报7.23港元，成交额1757.17万港元。　　齐鲁制药获同源康医药肺癌靶向创新药TY-9591独家商业化授权，齐鲁制药还将对同源康医药进行股权投资。　　公开资料显示，TY-9591是同源康医药自主研发的新一代高选择性不可逆EGFR-TKI，也是国内差异化优势突出的肺癌靶向新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-27/doc-inikfnpf3106086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1191","09939","BK1574","BK1515","159938","02410","01477","TY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654109998","title":"港股异动 | 同源康医药-B(02410.HK)午前涨超6% 齐鲁制药获TY-9591独家商业化授权 拟股权投资同源康","url":"https://stock-news.laohu8.com/highlight/detail?id=2654109998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654109998?lang=zh_cn&edition=full","pubTime":"2026-07-27 11:56","pubTimestamp":1785124614,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","01477","BK1574","BK1191","02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653698237","title":"同源康医药-B(02410)对四川汇宇制药股份有限公司提起法律程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2653698237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653698237?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:56","pubTimestamp":1784732193,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司最近已向长兴县人民法院提交一宗案件，对四川汇宇制药股份有限公司(汇宇)提起法律程序，寻求以下司法确认：一份声称与汇宇订立的TY-9591相关合作协议及经销协议并未成立且属无效。本公司亦收到内江市市中区人民法院就汇宇就据称由本公司与汇宇订立的同一合作协议、经销协议及相关文件所发出的案件受理通知书。两宗案件均已立案，惟尚未在法院审理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1191","BK1515","09939","02410","01477","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105550769","title":"同源康医药-B就TY-9591合作协议纠纷启动法律程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1105550769","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105550769?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:55","pubTimestamp":1784732129,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司7月22日发布公告称，公司已在长兴县人民法院对四川汇宇制药股份有限公司提起诉讼，要求法院确认双方所谓的TY-9591合作协议及经销协议“不成立且无效”。\\n\\n同源康医药-B同时透露，其亦收到内江市市中区人民法院就同一合作协议、经销协议及相关文件立案的受理通知书。两宗案件均已立案，但均尚未开庭审理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778219","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 与齐鲁制药达成战略合作加速TY-9591商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653778219?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:24","pubTimestamp":1784683457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","02410","09939","01477","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0848},{"period":"3month","weight":-0.1649},{"period":"6month","weight":-0.441},{"period":"1year","weight":-0.5735},{"period":"ytd","weight":-0.5267}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}